Filgotinib as Induction and Maintenance Therapy for Crohn's Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Gastroenterology & Hepatology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial
Lancet Gastroenterol Hepatol 2024 Dec 02;[EPub Ahead of Print], S Vermeire, S Schreiber, DT Rubin, G D'Haens, W Reinisch, M Watanabe, R Mehta, X Roblin, I Beales, P Gietka, T Hibi, I Hospodarskyy, T Ritter, MC Genovese, P Kwon, E Santermans, FO Le Brun, R Barron, T Masior, S DaneseFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.